Skip to main content
SpringerLink
Log in

Engineering of the Fc Region for Improved PK (FcRn Interaction)

  • Protocol
Antibody Engineering

Part of the book series: Springer Protocols Handbooks ((SPH))

Abstract

Interaction of antibodies with the neonatal FcRn receptor controls largely the length of their life cycle. Altering the serum persistence of antibodies through modulation of their interaction with the FcRn may be advantageous for achieving high contrast images shortly after application of the radiolabeled antibody tracer or more efficient therapy with fewer administrations. This protocol describes the steps required for producing antibodies, antibody fragments or antibody Fc fusion proteins with altered in vivo pharmacokinetics through introduction of specific mutations in the antibody Fc region. Included are also protocols for evaluation of binding to the FcRn in vitro and determination of serum half-life through radioiodinating the antibody Fc variants and performing biodistribution studies in mice.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 219.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 279.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 379.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Akilesh S, Christianson GJ, Roopenian DC, Shaw AS (2007) Neonatal FcR expression in bone marrow-derived cells functions to protect serum IgG from catabolism. J Immunol 179:4580–4588

    PubMed  CAS  Google Scholar 

  • Akilesh S, Huber TB, Wu H, Wang G, Hartleben B, Kopp JB, Miner JH, Roopenian DC, Unanue ER, Shaw AS (2008) Podocytes use FcRn to clear IgG from the glomerular basement membrane. Proc Natl Acad Sci USA 105:967–972

    Article  PubMed  CAS  Google Scholar 

  • Andersen JT, Justesen S, Berntzen G, Michaelsen TE, Lauvrak V, Fleckenstein B, Buus S, Sandlie I (2008a) A strategy for bacterial production of a soluble functional human neonatal Fc receptor. J Immunol Methods 331:39–49

    Article  PubMed  CAS  Google Scholar 

  • Andersen JT, Justesen S, Fleckenstein B, Michaelsen TE, Berntzen G, Kenanova VE, Daba MB, Lauvrak V, Buus S, Sandlie I (2008b) Ligand binding and antigenic properties of a human neonatal Fc receptor with mutation of two unpaired cysteine residues. Febs J 275:4097–4110

    Article  PubMed  CAS  Google Scholar 

  • Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC, Norton L (1999) Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Semin Oncol 26:78–83

    PubMed  CAS  Google Scholar 

  • Bauer RJ, Dedrick RL, White ML, Murray MJ, Garovoy MR (1999) Population pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hu1124 in human subjects with psoriasis. J Pharmacokinet Biopharm 27:397–420

    Article  PubMed  CAS  Google Scholar 

  • Baxter LT, Zhu H, Mackensen DG, Jain RK (1994) Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice. Cancer Res 54:1517–1528

    PubMed  CAS  Google Scholar 

  • Berntzen G, Lunde E, Flobakk M, Andersen JT, Lauvrak V, Sandlie I (2005) Prolonged and increased expression of soluble Fc receptors, IgG and a TCR-Ig fusion protein by transiently transfected adherent 293E cells. J Immunol Methods 298:93–104

    Article  PubMed  CAS  Google Scholar 

  • Burmeister WP, Huber AH, Bjorkman PJ (1994) Crystal structure of the complex of rat neonatal Fc receptor with Fc. Nature 372:379–383

    Article  PubMed  CAS  Google Scholar 

  • Covell DG, Barbet J, Holton OD, Black CD, Parker RJ, Weinstein JN (1986) Pharmacokinetics of monoclonal immunoglobulin G1, F(ab')2, and Fab' in mice. Cancer Res 46:3969–3978

    PubMed  CAS  Google Scholar 

  • Dall’Acqua WF, Woods RM, Ward ES, Palaszynski SR, Patel NK, Brewah YA, Wu H, Kiener PA, Langermann S (2002) Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences. J Immunol 169:5171–5180

    PubMed  Google Scholar 

  • Dall'Acqua WF, Kiener PA, Wu H (2006) Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem 281:23514–23524

    Article  PubMed  Google Scholar 

  • Flessner MF, Lofthouse J, Zakaria el-R (1997) In vivo diffusion of immunoglobulin G in muscle: effects of binding, solute exclusion, and lymphatic removal. Am J Physiol 273:H2783–H2793

    PubMed  CAS  Google Scholar 

  • Ghetie V, Popov S, Borvak J, Radu C, Matesoi D, Medesan C, Ober RJ, Ward ES (1997) Increasing the serum persistence of an IgG fragment by random mutagenesis. Nat Biotechnol 15:637–640

    Article  PubMed  CAS  Google Scholar 

  • Gillies SD, Lo KM, Burger C, Lan Y, Dahl T, Wong WK (2002) Improved circulating half-life and efficacy of an antibody-interleukin 2 immunocytokine based on reduced intracellular proteolysis. Clin Cancer Res 8:210–216

    PubMed  CAS  Google Scholar 

  • Haymann JP, Levraud JP, Bouet S, Kappes V, Hagege J, Nguyen G, Xu Y, Rondeau E, Sraer JD (2000) Characterization and localization of the neonatal Fc receptor in adult human kidney. J Am Soc Nephrol 11:632–639

    PubMed  CAS  Google Scholar 

  • Hinton PR, Xiong JM, Johlfs MG, Tang MT, Keller S, Tsurushita N (2006) An engineered human IgG1 antibody with longer serum half-life. J Immunol 176:346–356

    PubMed  CAS  Google Scholar 

  • Kenanova V, Olafsen T, Crow DM, Sundaresan G, Subbarayan M, Carter NH, Ikle DN, Yazaki PJ, Chatziioannou AF, Gambhir SS, Williams LE, Shively JE, Colcher D, Raubitschek AA, Wu AM (2005) Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments. Cancer Res 65:622–631

    PubMed  CAS  Google Scholar 

  • Kim JK, Tsen MF, Ghetie V, Ward ES (1994) Localization of the site of the murine IgG1 molecule that is involved in binding to the murine intestinal Fc receptor. Eur J Immunol 24:2429–2434

    Article  PubMed  CAS  Google Scholar 

  • Kuus-Reichel K, Grauer LS, Karavodin LM, Knott C, Krusemeier M, Kay NE (1994) Will immunogenicity limit the use, efficacy, and future development of therapeutic monoclonal antibodies? Clin Diagn Lab Immunol 1:365–372

    PubMed  CAS  Google Scholar 

  • Lobo ED, Hansen RJ, Balthasar JP (2004) Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 93:2645–2668

    Article  PubMed  CAS  Google Scholar 

  • Mager DE, Mascelli MA, Kleiman NS, Fitzgerald DJ, Abernethy DR (2003) Simultaneous modeling of abciximab plasma concentrations and ex vivo pharmacodynamics in patients undergoing coronary angioplasty. J Pharmacol Exp Ther 307:969–976

    Article  PubMed  CAS  Google Scholar 

  • Medesan C, Radu C, Kim JK, Ghetie V, Ward ES (1996) Localization of the site of the IgG molecule that regulates maternofetal transmission in mice. Eur J Immunol 26:2533–2536

    Article  PubMed  CAS  Google Scholar 

  • Medesan C, Matesoi D, Radu C, Ghetie V, Ward ES (1997) Delineation of the amino acid residues involved in transcytosis and catabolism of mouse IgG1. J Immunol 158:2211–2217

    PubMed  CAS  Google Scholar 

  • Meier W, Gill A, Rogge M, Dabora R, Majeau GR, Oleson FB, Jones WE, Frazier D, Miatkowski K, Hochman PS (1995) Immunomodulation by LFA3TIP, an LFA-3/IgG1 fusion protein: cell line dependent glycosylation effects on pharmacokinetics and pharmacodynamic markers. Ther Immunol 2:159–171

    PubMed  CAS  Google Scholar 

  • Meijer RT, Koopmans RP, ten Berge IJ, Schellekens PT (2002) Pharmacokinetics of murine anti-human CD3 antibodies in man are determined by the disappearance of target antigen. J Pharmacol Exp Ther 300:346–353

    Article  PubMed  CAS  Google Scholar 

  • Montoyo HP, Vaccaro C, Hafner M, Ober RJ, Mueller W, Ward ES (2009) Conditional deletion of the MHC class I-related receptor FcRn reveals the sites of IgG homeostasis in mice. Proc Natl Acad Sci USA 106:2788–2793

    Article  PubMed  CAS  Google Scholar 

  • Newkirk MM, Novick J, Stevenson MM, Fournier MJ, Apostolakos P (1996) Differential clearance of glycoforms of IgG in normal and autoimmune-prone mice. Clin Exp Immunol 106:259–264

    Article  PubMed  CAS  Google Scholar 

  • Ober RJ, Radu CG, Ghetie V, Ward ES (2001) Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. Int Immunol 13:1551–1559

    Article  PubMed  CAS  Google Scholar 

  • Petkova SB, Akilesh S, Sproule TJ, Christianson GJ, Al Khabbaz H, Brown AC, Presta LG, Meng YG, Roopenian DC (2006) Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease. Int Immunol 18:1759–1769

    Article  PubMed  CAS  Google Scholar 

  • Qiao SW, Kobayashi K, Johansen FE, Sollid LM, Andersen JT, Milford E, Roopenian DC, Lencer WI, Blumberg RS (2008) Dependence of antibody-mediated presentation of antigen on FcRn. Proc Natl Acad Sci USA 105:9337–9342

    Article  PubMed  CAS  Google Scholar 

  • Raghavan M, Bonagura VR, Morrison SL, Bjorkman PJ (1995) Analysis of the pH dependence of the neonatal Fc receptor/immunoglobulin G interaction using antibody and receptor variants. Biochemistry 34:14649–14657

    Article  PubMed  CAS  Google Scholar 

  • Roopenian DC, Akilesh S (2007) FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 7:715–725

    Article  PubMed  CAS  Google Scholar 

  • Waldmann TA, Strober W (1969) Metabolism of immunoglobulins. Prog Allergy 13:1–110

    PubMed  CAS  Google Scholar 

  • Wawrzynczak EJ, Cumber AJ, Parnell GD, Jones PT, Winter G (1992) Blood clearance in the rat of a recombinant mouse monoclonal antibody lacking the N-linked oligosaccharide side chains of the CH2 domains. Mol Immunol 29:213–220

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at University of California Los Angeles, 570 Westwood Plaza, Los Angeles, CA, 90095, USA

    Vania E. Kenanova, Tove Olafsen & Anna M. Wu

  2. Department of Molecular Biosciences and Centre for Immune Regulation, University of Oslo, Olso, Norway

    Jan T. Andersen & Inger Sandlie

Authors
  1. Vania E. Kenanova
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tove Olafsen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jan T. Andersen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Inger Sandlie
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Anna M. Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anna M. Wu .

Editor information

Editors and Affiliations

  1. (Biomedical Engineering) Institut für Zellbiologie und Immunologie, Universität Stuttgart, Allmandring 31, 70569, Stuttgart, Germany

    Roland Kontermann

  2. Technische Universität Braunschweig, Institut für Biochemie und Biotechnologie, Spielmannstraße 7, 38106, Braunschweig, Germany

    Stefan Dübel

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer-Verlag

About this protocol

Cite this protocol

Kenanova, V.E., Olafsen, T., Andersen, J.T., Sandlie, I., Wu, A.M. (2010). Engineering of the Fc Region for Improved PK (FcRn Interaction). In: Kontermann, R., Dübel, S. (eds) Antibody Engineering. Springer Protocols Handbooks. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-01144-3_27

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-01144-3_27

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-01143-6

  • Online ISBN: 978-3-642-01144-3

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation